Business · 16/04/2026Updated: 10/16/2026 · 1 min read
FDA Approves COVID-19 Vaccine MNEXSPIKE for Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved MNEXSPIKE, a COVID-19 vaccine, for a rare pediatric disease priority review voucher, following its May 30, 2025, approval.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →